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Background and aims: Mast cells have been implicated in the development and progression of athero-
sclerosis in animal models and human autopsy studies. However, it is unknown whether long-term
exposure to excess of mast cells is associated with cardiovascular disease (CVD) in humans. Our objec-
tive was to compare the prevalence of CVD and cardiovascular risk factors in patients with systemic
mastocytosis (SM) and controls.
Methods: In 50 patients with SM and 50 age and sex matched controls, the history of CVD and presence
of cardiovascular risk factors were assessed. Carotid ultrasound was performed to assess carotid intima-
media thickness (C-IMT) and plaques presence.
Results: CVD events were more prevalent in SM patients compared to controls (20% vs. 6%, p ¼ 0.04). The
prevalence of C-IMT and carotid plaques was similar between patients with SM and controls. In multi-
variate analysis, CVD events were significantly associated with SM (OR 7.0 (95% CI 1.3e37.6), p ¼ 0.02)
and hypertension (OR 9.5 (95% CI 1.9e48.7), p ¼ 0.01). The prevalence of diabetes, hypertension, obesity
and smoking was similar between the two groups. Total cholesterol and LDL-C levels were significantly
lower in SM patients than in the control group. (5.1 ± 1.1 vs. 5.9 ± 0.9 mmol/l, p < 0.05 and 2.9 ± 0.8 vs.
3.5 ± 0.7 mmol/l, p < 0.05, respectively).
Conclusions: Despite lower plasma total cholesterol and LDL-C, the prevalence of CVD is higher in pa-
tients with SM compared to healthy controls. Beyond the setting of SM, this study can be considered as a
proof of concept study, indicating the contribution of mast cells to CVD in humans.
© 2018 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute cardiovascular syndromes such as myocardial infarction
and stroke are a major cause of morbidity andmortality worldwide,
caused by the development of atherosclerosis in the arterial wall
[1]. Inflammation, matrix degradation and lipid accumulation are
generally considered key processes in atherosclerosis and the
pathogenesis of atherosclerotic plaque rupture [2]. The mast cell, a
prominent inflammatory cell type and a major effector cell in al-
lergy and asthma, has also been associated with cardiovascular40, 3000 CA Rotterdam, The
(J.E. Roeters van Lennep).
25, 3015 CE Rotterdam, The
Ireland Ltd. This is an open accessdisease (CVD) [3]. In human pathology studies, it was established
that mast cells accumulate both in the rupture-prone shoulder
region of coronary atheromas [4,5] and in the perivascular tissue
during atherosclerotic lesion progression [6e8]. Particularly, in
advanced stages of atherosclerosis, the number of mast cells is high
[5]. In experimental mouse models, activation of perivascular mast
cells on the one hand promoted atherosclerotic plaque destabili-
zation [9], while on the other hand, mast cell deficiency limited
atherogenesis [10]. Together, these data suggest that mast cells,
containing a large number of proteases and pro-inflammatory
mediators, are causally linked to plaque destabilization and even
rupture, underlining the importance of mast cells in CVD.
Systemic mastocytosis (SM) is a disease characterized by an
accumulation of mast cells in one ormore organs. Manifestations of
the disease are largely provoked by the resultant increase in mast
cell-derived mediators, which have a variety of local and systemicarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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combination of major and minor criteria according to the World
Health Organization's (WHO). If at least onemajor and oneminor or
at least three minor SM criteria are fulfilled, the diagnosis of SM is
made [11]. SM is further divided into four distinct disorders:
indolent systemic mastocytosis (ISM), SM with an associated he-
matologic neoplasm (SM-AHN), aggressive systemic mastocytosis
(ASM), and mast cell leukemia (MCL). The most common form is
indolent SM of which the smouldering SM is a subtype defined by
the presence of organ involvement without organ dysfunction [12].
In view of the aforementioned effects of mast cell activation on
atherogenesis and atherosclerotic plaque destabilization, we hy-
pothesize that patients with SM have more advanced atheroscle-
rosis and/or more adverse cardiovascular risk factors compared to
subjects without SM. In this study, we thus aimed to compare the
prevalence of CVD and cardiovascular risk factors in patients with
SM and age- and sex-matched controls.
2. Patients and methods
2.1. Study population
The Immunology department of the Erasmus Medical Center
treats a large cohort of patients with SM as expertise center on
mastocytosis, as recently described by Hermans et al. [12] Subjects
were enrolled between April 2014 and July 2015. SM patients were
invited to participate in the study. Subjects for the control group
were collected by asking the SM patients to bring another person
not diagnosed with SM, preferably of the same age and sex. If a
patient was not able to bring a subject for the control group, the
investigators provided a subject through advertisement in the
hospital. Inclusion criterion for all subjects was age older than 18
years. An additional inclusion criterion, solely for the SM patients,
was having met theWHO criteria for the diagnosis of SM. The study
complied with the Declaration of Helsinki and written informed
consent for the use of clinical data and for blood storage was ob-
tained from all subjects. The study was approved by the Medical
Ethics Committee of the Erasmus MC (MEC-2013-556).
2.2. Data collection
We acquired clinical data by using a standard questionnaire,
comprising medical history, including history of cardiovascular
events and cardiovascular risk factors. Moreover, information on
medication use was obtained. Blood pressure, length and weight
were measured in all subjects. Smoking was defined as both pre-
vious and current smoking.
Overnight fasting blood samples were collected for measure-
ment of fasting glucose and lipid profile total cholesterol, tri-
glycerides, low-density lipoprotein-cholesterol (LDL-C), high-
density lipoprotein-cholesterol (HDL-C), apolipoprotein-AI (ApoA-
I), apolipoprotein-B (ApoB), lipoprotein(a) (Lp(a)), which were
determined using the standard laboratory techniques. Untreated
LDL-C levels before statin use were retrieved. If this information
was not available, untreated LDL-C was calculated using the con-
version factor for statin and dosage being used [13,14].
Carotid intima-media thickness (C-IMT) and the presence of
carotid plaques were assessed using the Panasonic Cardio Health
Station as described by Bos et al. [15] Plaques were scored as pre-
sent or absent. In this study, C-IMT indicates the mean of the left
and right mean C-IMT.
Cardiovascular disease (CVD) events were defined as coronary
heart disease (CHD) classified by myocardial infarction, resusci-
tated cardiac arrest and angina pectoris followed or not by coronary
revascularization, cerebrovascular events and/or the presence ofperipheral arterial vascular disease.
Cerebrovascular events were defined by history of stroke and
transient ischemic attacks. Peripheral vascular disease was defined
by symptoms of claudication diagnosed by a vascular surgeon and/
or revascularization of the peripheral vasculature.
2.3. Statistical analysis
Statistical analysis was conducted using SPSS, version 21. Results
are presented as mean ± standard deviation (S.D.). Categorical
variables were compared using Pearson's Chi-square. Continuous
variables were compared using Student's t-test when normally
distributed; the Mann-Whitney U test was used when variables
were not normally distributed. Logistic regression analysis was
used to evaluate the association between CVD and the known
cardiovascular risk indicators such as age, sex, body mass index,
smoking, hypertension, untreated LDL-C levels and diabetes mel-
litus. Linear regression analysis was applied to evaluate the asso-
ciation between C-IMT and the aforementioned potentially
confounding cardiovascular risk factors. The association between
SM and C-IMT was evaluated by use of a linear regression model,
the association between SM and CVD events and plaques by use of a
logistic regression model. Results were considered statistically
significant if the corresponding p-value was <0.05.
3. Results
The demographic and clinical data are shown in Table 1. We
enrolled 50 patients with SM and 50 controls. The mean age was
similar in the two groups (60 ± 11 years in the SM group and
59 ± 10 years in the control group, p ¼ 0.86). Sex was equally
distributed in both groups. The other baseline characteristics were
also similar in the two groups.
Within the group of patients with SM, most patients had indo-
lent SM, 1 had smouldering SM and 2 had SM with an associated
hematologic neoplasm, i.e. chronic myelomonocytic leukemia
(CMMoL) and acute myeloid leukemia (AML).
3.1. Cardiovascular disease
Carotid ultrasound showed that the prevalence of carotid artery
plaques and C-IMT was similar between patients with SM
compared to controls (54% vs. 38%, p ¼ 0.11 and 0.65 ± 0.11 mm vs.
0.64 ± 0.13 mm, p ¼ 0.65 respectively). In 77% of all cases with CVD
events, plaques were present. Despite the lack of differences in C-
IMT, CVD events were more prevalent in patients with SM
compared to controls (20% vs. 6%, p ¼ 0.04). The CVD events con-
sisted mainly of CHD (10% in SM patients and 4% in controls) and
cerebrovascular events (10% and 2% respectively). Two subjects in
the SM group had had 2 types of CVD events (Table 1).
In multivariable regression analyses, CVD events were signifi-
cantly associated with SM (p ¼ 0.02) and hypertension (p ¼ 0.01)
(Table 2).
There were no significant associations between SM and plaque
presence (p ¼ 0.22) and C-IMT (p ¼ 0.57). In addition, no other
variable except agewas associated with C-IMT (p < 0.001) (Table 3).
The mean tryptase concentration was somewhat higher in the
group of SM patients with CVD events in comparison to SM patients
without CVD (79.4 ± 83.5 mg/L vs. 54.2 ± 59 mg/L respectively,
p ¼ 0.273).
3.2. Cardiovascular risk factors
The prevalence of diabetes, hypertension, obesity and smoking
did not differ between patients with SM and controls.
Table 1
Baseline characteristics.
Characteristics SM (n ¼ 50) Controls (n ¼ 50) p-value
Age, mean ± SD (y) 60 ± 11 59 ± 10 0.86
Male (n, %) 25 (50) 25 (50) 1.00
BMI, mean ± SD (kg/m2) 27 ± 4 27 ± 5 0.90
Waist, mean ± SD (cm) 97 ± 11 96 ± 14 0.70
Systolic blood pressure, mean ± SD (mmHg) 146 ± 20 146 ± 21 0.93
Diastolic blood pressure, mean ± SD (mmHg) 86 ± 10 89 ± 12 0.15
Diabetes (n, %)a 5 (10) 1 (2) 0.09
Fasting blood glucose, mean ± SD (mmol/L) 5.6 ± 1.3 5.4 ± 0.7 0.44
Hypertension (n, %)b 17 (34) 14 (28) 0.52
Hypercholesterolaemia (n, %)c 12 (24) 9 (18) 0.46
Statin medication (n, %) 10 (20) 7 (14) 0.42
Smoking (n, %)d 27 (54) 27 (54) 1.00
Plaques (n, %) 27 (54) 19 (38) 0.11
IMT, mean ± SD (mm) 0.65 ± 0.11 0.64 ± 0.13 0.65
Cardiovascular disease events (n, %)e 10 (20) 3 (6) 0.04
Cerebrovascular events (n, %) 5 (10) 1 (2) 0.09
Peripheral arterial disease (n, %) 2 (4) 0 (0) 0.15
Coronary heart disease (CHD) events (n, %)f 5 (10) 2 (4) 0.24
a Diabetes is defined by the use of anti-diabetic medication.
b Hypertension is defined by the use of anti-hypertensive medication.
c Hypercholesterolaemia is defined by the use of statins and/or reported presence of hypercholesterolaemia.
d Smoking includes both previous and current smoking.
e Cardiovascular disease includes cerebrovascular and coronary heart disease events and peripheral arterial disease. All patients used aspirin 80e100 mg per day.
f Coronary heart disease events include myocardial infarction and coronary interventions.
Table 2
Multivariable regression analyses with CVD as dependent variable.
Variable OR (95% CI) p-value
Age 1.0 (0.9e1.1) 0.73
Male 1.6 (0.4e7.1) 0.54
BMI 1.0 (0.8e1.3) 0.90
Hypertension 9.5 (1.9e48.7) 0.01
Smoking 1.3 (0.3e5.7) 0.72
Diabetes 0.22 (0.2e3.4) 0.28
LDL-cholesterol without statina 1.6 (0.7e3.7) 0.28
Systemic mastocytosis 7.0 (1.3e37.6) 0.02
a LDL-cholesterol without statin are based on untreated LDL-C levels or calculated
with the conversion factor for the statin being used.
Table 3
Multivariable regression analyses with plaques and C-IMT as dependent variables.a
Variable Plaques C-IMT
OR (95% CI) p-value Beta (b) p-value
Age 1.0 (1.0e1.1) 0.09 0.61 <0.001
Male 1.0 (0.4e2.6) 0.97 -0.08 0.39
BMI 1.0 (0.9e1.1) 0.49 0.11 0.19
Hypertension 2.6 (0.9e7.5) 0.08 -0.03 0.75
Smoking 1.1 (0.4e2.7) 0.89 0.06 0.45
Diabetes 0.0 (0.0 -.) 0.99 -0.08 0.38
LDL-cholesterol without statin 1.1 (0.7e1.1) 0.77 -0.02 0.78
Systemic mastocytosis 1.8 (0.7e4.7) 0.22 0.05 0.57
a In the multivariable linear regression analyses of C-IMT the adjusted R2 ¼ 0.333.
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the SM patients than in the control group (5.1 ± 1.1 vs.
5.9 ± 0.9 mmol/L, p < 0.001 and 2.9 ± 0.8 vs. 3.5 ± 0.7 mmol/L,
p < 0.001, respectively, Fig. 1A). SM patients used statins more
frequently, yet untreated LDL-C levels were significantly lower in
the SM patient group compared to controls (3.2 ± 0.8 vs.
3.7 ± 0.8 mmol/L, p ¼ 0.01). Levels of ApoA-I and ApoB were
significantly lower in the SM patients compared to the control
group (1.6 ± 0.4 vs. 1.9 ± 0.3 mmol/L, p < 0.001, and 0.9 ± 0.2 vs.
1.1 ± 0.2 g/L, p ¼ 0.02 respectively, Fig. 1B). Concentrations of HDL-
C, TG and Lp(a) were similar in the two groups (Fig. 1A and B).The mean tryptase concentrationwas not associated with LDL-C
levels in patients with SM (p ¼ 0.08).4. Discussion
In the present study, we showed that patients with SM
compared to healthy age- and sex-matched controls had a higher
prevalence of cardiovascular events despite lower plasma lipid
levels.
Acute cardiovascular events usually arise from rupture of an
atherosclerotic plaque, and mast cells have been shown to accu-
mulate in the rupture prone shoulder regions of the plaques [5]. In
experimental animal models, the activation of perivascular mast
cells promote plaque destabilization [9], and it was shown in hu-
man carotid endarterectomy specimen that intraplaque mast cell
numbers positively correlated with disease progression and
destabilization [16]. The mast cell was actually the only inflam-
matory cell type predictive for the incidence of future cardiovas-
cular events. Kupreishvili et al. recently showed, in a human
pathology study, the presence of mast cells in the intima andmedia
of both stable and unstable atherosclerotic coronary lesions after
myocardial infarction. Mast cells were significantly increased in the
media of unstable plaques in patients who experienced a myocar-
dial infarction 5e14 days earlier [17]. These findings suggest that
mast cells present in coronary lesions may contribute to the onset
of myocardial infarction through plaque destabilization.
Our study showed that the incidence of CVD events is higher in
patients with SM, and thus with increased mast cell numbers,
compared to that in amatched control group, hence also suggesting
that mast cells contribute to atherosclerotic plaque destabilization.
In line with the findings from our study, Broesby-Olsen et al.
showed that within a nationwide population-based cohort, SM
patients had an increased risk of stroke, as well as a non-significant
increase in risk of myocardial infarction, with hazard ratios be-
tween 1 and 2 [18].
To our knowledge, we are the first to observe reduced plasma
total cholesterol, LDL-C, ApoA-I and ApoB levels in patients with SM
compared to controls. Mast cells have previously been reported to
inhibit the functionality of HDL-C in reverse cholesterol transport
Fig. 1. Lipid profiles in patients with systemic mastocytosis and controls.
(A) TC, total cholesterol; TG, triglycerides, LDL-C; low-density lipoprotein-cholesterol
without statin; HDL-C ¼ high-density lipoprotein. (B) ApoA-I, apolipoprotein-AI;
ApoB, apolipoprotein-B; Lp(a), lipoprotein(a). Results are presented as mean ± SD,
except for TG and Lp(a), which are presented as median (IQR). Error bars represent 95%
CI. p < 0.05 is considered statistically significant and is represented by an asterisk (*).
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Recently, it was established that chymase cleaves ApoA-I resulting
in loss of its anti-inflammatory functions [20]. Moreover, cathepsin
G, another protease released from mast cells, has been reported to
degrade LDL, reducing LDL-C and ApoB levels [21]. Excessive mast
cell protease activity in SM patients may be, at least in part,
responsible for the altered apolipoprotein profile observed. Despite
the “beneficial” lipid levels, which would suggest limited athero-
sclerotic lesion development in carotids of SM patients, lesion
incidence was not different between the groups. The incidence ofcardiovascular events was even higher in the SM group, suggesting
that plaque stability was reduced in SM patients. We have previ-
ously established that chymase is one of the key players in mast
cell-induced plaque destabilization [22], and tryptase has also been
associated with plaque instability. Our findings support this hy-
pothesis and suggest that mast cells contribute significantly to
plaque destabilization.
Although the number of patients and cardiovascular events may
seem small, the strength of our study is the complete cardiovas-
cular phenotyping in a substantial population of patients with SM,
considering the rareness of disease. This study can, thus, be regar-
ded as an important pilot, which justifies the initiation of further
research, preferably a prospective long-term follow-up study of a
large cohort of SM patients and matched controls to further
investigate the risk of cardiovascular disease in these patients.
4.1. Conclusions
We found a significantly higher prevalence of CVD events and
lower plasma lipid levels in patients with SM compared to a control
group. To our knowledge, this is the first study to investigate the
prevalence of cardiovascular disease in relationwith cardiovascular
risk factors among patients with SM, supporting the evidence that
mast cells contribute to atherosclerosis and CVD events in patients
with SM and implying the pathogenicity of mast cells via plaque
destabilization. In clinical context, cardiovascular screening in pa-
tients with SM seems warranted. Furthermore, we believe that
these results reach beyond the setting of SM and can be considered
as a proof of concept study, which unifies and strengthens insights
learned from experimental atherosclerosis studies, reinforcing the
concept of the contribution of mast cells to cardiovascular diseases
in humans.
Conflict of interest
The authors declared they do not have anything to disclose
regarding conflict of interest with respect to this manuscript.
Financial support
I. Bot is supported by a Dr. Dekker Senior Postdoc grant from the
Netherlands Heart Foundation (2012T083).
Author contributions
Roeters van Lennep and Indhirajanti had full access to all the
data in the study and take responsibility for the integrity of the data
and the accuracy of the data analysis.
Roeters van Lennep, Indhirajanti, Van Daele and Bot designed
and performed research, analyzed data and wrote the article; Bos
and Mulder contributed in the acquisition of data.
References
[1] P.K. Shah, Mechanisms of plaque vulnerability and rupture, J. Am. Coll. Cardiol.
41 (2003) 15Se22S.
[2] G. Stoll, M. Bendszus, Inflammation and atherosclerosis: novel insights into
plaque formation and destabilization, Stroke 37 (7) (2006) 1923e1932,
https://doi.org/10.1161/01.STR.0000226901.34927.10.
[3] I. Bot, G.P. Shi, P.T. Kovanen, Mast cells as effectors in atherosclerosis, Arte-
rioscler. Thromb. Vasc. Biol. 35 (2) (2015) 265e271, https://doi.org/10.1161/
ATVBAHA.114.303570.
[4] M. Kaartinen, A. Penttil€a, P.T. Kovanen, Accumulation of activated mast cells in
the shoulder region of human coronary atheroma, the predilection site of
atheromatous rupture, Circulation 90 (4) (1994) 1669e1678.
[5] P.T. Kovanen, M. Kaartinen, T. Paavonen, Infiltrates of activated mast cells at
the site of coronary atheromatous erosion or rupture in myocardial infarction,
Circulation 92 (5) (1995) 1084e1088.
S. Indhirajanti et al. / Atherosclerosis 268 (2018) 152e156156[6] P. Laine, M. Kaartinen, A. Penttil€a, P. Panula, T. Paavonen, P.T. Kovanen, As-
sociation between myocardial infarction and the mast cells in the adventitia of
the infarct-related coronary artery, Circulation 99 (3) (1999) 361e369.
[7] P. Laine, A. Naukkarinen, L. Heikkil€a, A. Penttil€a, P.T. Kovanen, Adventitial mast
cells connect with sensory nerve fibers in atherosclerotic coronary segments,
Circulation 101 (14) (2000) 1665e1669.
[8] M. Kaartinen, A.C. van der Wal, C.M. van der Loos, K.T. Koch, A.E. Becker,
P.T. Kovanen, Mast cell infiltration in acute coronary syndromes: implications
for plaque rupture, J. Am. Coll. Cardiol. 32 (3) (1998) 606e612.
[9] I. Bot, S.C. de Jager, A. Zernecke, K.A. Lindstedt, T.J. van Berkel, C. Weber,
E.A. Biessen, Perivascular mast cells promote atherogenesis and induce plaque
destabilization in apoE deficient mice, Circulation 115 (19) (2007) 2516e2525,
https://doi.org/10.1161/CIRCULATIONAHA.106.660472.
[10] J. Sun, G.K. Sukhova, P.J. Wolters, M. Yang, S. Kitamoto, P. Libby,
L.A. MacFarlane, J. Mallen-St Clair, G.P. Shi, Mast cells promote atherosclerosis
by releasing proinflammatory cytokines, Nat. Med. 13 (6) (2007) 719e724,
https://doi.org/10.1038/nm1601.
[11] H.P. Horny, C. Akin, D.D. Metcalfe, et al., Mastocytosis (mast cell disease), in:
S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele,
J.W. Vardiman (Eds.), World Health Organization (WHO) Classification of
Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid
Tissues, IARC Press, Lyon, 2008, pp. 54e63.
[12] M.A. Hermans, M.J. Rietveld, J.A. van Laar, V.A. Dalm, M. Verburg,
S.G. Pasmans, R. Gerth van Wijk, P.M. van Hagen, P.L. van Daele, Systemic
mastocytosis: a cohort study on clinical characteristics of 136 patients in a
large tertiary centre, Eur. J. Intern Med. 30 (2016) 25e30, https://doi.org/
10.1016/j.ejim.2016.01.005.
[13] M.H. Davidson, T. McGarry, R. Bettis, L. Melani, L.J. Lipka, A.P. LeBeaut,
R. Suresh, S. Sun, E.P. Veltri, Ezetimibe co-administered with simvastatin in
patients with primary hypercholesterolemia, J. Am. Coll. Cardiol. 40 (12)
(2002) 2125e2134.
[14] M.R. Law, N.J. Wald, A.R. Rudnicka, Quantifying effect of statins on low density
lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic re-
view and meta-analysis, BMJ 326 (7404) (2003) 1423.
[15] S. Bos, M.H. Duvekot, A.C. Touw-Blommesteijn, A.J. Verhoeven, M.T. Mulder,
G.F. Watts, E.J. Sijbrands, J.E. Roeters van Lennep, Lipoprotein (a) levels are not
associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia, Atherosclerosis 242 (1)
(2015) 226e229, https://doi.org/10.1016/j.atherosclerosis.2015.07.024.
[16] S. Willems, A. Vink, I. Bot, P.H. Quax, G.J. de Borst, J.P. de Vries, S.M. van de
Weg, F.L. Moll, J. Kuiper, P.T. Kovanen, D.P. de Kleijn, I.E. Hoefer,
G. Pasterkamp, Mast cells in human carotid atherosclerotic plaques are
associated with intraplaque microvessel density and the occurrence of future
cardiovascular events, Eur. Heart J. 34 (48) (2013) 3699e3706, https://doi.org/
10.1093/eurheartj/eht186.
[17] K. Kupreishvili, W.W. Fuijkschot, A.B. Vonk, Y.M. Smulders, W. Stooker,
V.W. Van Hinsbergh, et al., Mast cells are increased in the media of coronary
lesions in patients with myocardial infarction and may favor atherosclerotic
plaque instability, J. Cardiol. (2016 Jun 7), https://doi.org/10.1016/
j.jjcc.2016.04.018 pii: S0914e5087(16)30089-2.
[18] S. Broesby-Olsen, D.K. Farkas, H. Vestergaard, A.P. Hermann, M.B. Møller,
C.G. Mortz, et al., Risk of solid cancer, cardiovascular disease, anaphylaxis,
osteoporosis and fractures in patients with systemic mastocytosis: a nation-
wide population-based study, Am. J. Hematol. 91 (11) (2016 Nov) 1069e1075.
[19] I. Judstr€om, H. Jukkola, J. Metso, M. Jauhiainen, P.T. Kovanen, M. Lee-Rueckert,
Mast cell-dependent proteolytic modification of HDL particles during
anaphylactic shock in the mouse reduces their ability to induce cholesterol
efflux from macrophage foam cells ex vivo, Atherosclerosis 208 (1) (2010)
148e154, https://doi.org/10.1016/j.atherosclerosis.2009.07.027.
[20] S.D. Nguyen, K. Maaninka, J. Lappalainen, K. Nurmi, J. Metso, K. €O€orni,
M. Navab, A.M. Fogelman, M. Jauhiainen, M. Lee-Rueckert, P.T. Kovanen,
Carboxyl-terminal cleavage of apolipoprotein A-I by human mast cell chy-
mase impairs its anti-inflammatory properties, Arterioscler. Thromb. Vasc.
Biol. 36 (2) (2016) 274e284, https://doi.org/10.1161/ATVBAHA.115.306827.
[21] J. Wang, S. Sj€oberg, T.T. Tang, K. O€orni, W. Wu, C. Liu, B. Secco, V. Tia,
G.K. Sukhova, C. Fernandes, A. Lesner, P.T. Kovanen, P. Libby, X. Cheng,
G.P. Shi, Cathepsin G activity lowers plasma LDL and reduces atherosclerosis,
Biochim. Biophys. Acta 1842 (11) (2014 Nov) 2174e2183, https://doi.org/
10.1016/j.bbadis.2014.07.026.
[22] I. Bot, M. Bot, S.H. van Heiningen, P.J. van Santbrink, I.M. Lankhuizen,
P. Hartman, S. Gruener, H. Hilpert, T.J. van Berkel, J. Fingerle, E.A. Biessen, Mast
cell chymase inhibition reduces atherosclerotic plaque progression and im-
proves plaque stability in apoE-/- mice, Cardiovasc Res. 89 (1) (2011)
244e252, https://doi.org/10.1093/cvr/cvq260.
